Taphicidumab, Lancotia, and Selenex - What's the Thinking?

I'm curious, particularly in terms of taphicidumab, lancotia, and selenex. What the plans are, or strategies are in terms of future developments? With polytismab, if it's broad front line, I mean, we will use eventually for one or two cycles when we want to control the disease before CAR-T collection or for bridging. But I think it will not be a standard regimen for patients who have received it in front line. Regarding Selenexo, there were some attempts to develop a second generation of drugs targeting the same pathway. If this comes true and it's better tolerable, that will be an interesting